HealthMore in Health→
Phase 2 Trial Suggests Elraglusib Extends Survival in Metastatic Pancreatic Cancer
Key Takeaways
- Phase 2 trial compared elraglusib plus gemcitabine/nab-paclitaxel against chemotherapy alone in untreated metastatic pancreatic cancer.
- Median overall survival was 10.1 months with elraglusib versus 7.2 months for chemotherapy alone.
- One-year survival reached 44.1% in the combination arm compared with 22.3% in the control arm.
DE
DT Editorial Team··via nature.com
